Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advantan ointment dose duration-response study in healthy volunteers
ACTRN12622001295730Phase 4Completed
- Sponsor
- Zenith Technologies
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylprednisolone aceponate in atopic dermatitis (AD) and psoriasis, sponsored by Zenith Technologies. Primary endpoints: ED50 parameter of Advantan ointment, D1 parameter of Advantan ointment and 1 more. Started Dec 2022; status: completed.
02
Drugs
methylprednisolone aceponate
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on ACTRN12622001295730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001295730.